TRENDLINE

The Current State of the Rare Disease Market

Getty Images

Rare diseases are often monogenic, making them well-suited for genetic and precision therapies. Explore how regulatory shifts, pricing challenges and gene therapy's ongoing market woes are reshaping business strategies for rare diseases in this Trendline from our sister publication PharmaVoice.

Access now to learn:

Novartis’ Zolgensma sales fall again as gene therapy market woes persist
FDA’s new mission to speed drug reviews
How a patient group tackled research diversity for one disease and triggered change for pharma

For these insights and more, access the Trendline.

This Trendline is independently produced by our journalists. The support of our sponsors makes this journalism possible. Want to learn about sponsorship opportunities? Contact us directly at advertising@industrydive.com.

Want to reach 108,000+ biopharma executives with your own message? Get the media kit or contact us directly at advertising@industrydive.com.

About this email: You are receiving this message as part of your complimentary newsletter subscription to BioPharma Dive. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. BioPharma Dive is a product of TechTarget, Inc. and its subsidiaries, 275 Grove St. Newton, MA, 02466